All In Biotech

NDA 021957 · Astrazeneca

Nexium

Esomeprazole Magnesium · Oral

Last checked: Nov 20, 2026Latest source record: Jul 18, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2006

Oct 20, 2006

Approved uses

3

Original approval plus efficacy supplements

Registered trials

522

102 Phase 3, 23 recruiting

FAERS reports

184,794

125,906 serious, 14,871 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Dec 19, 2025.

NEXIUM is a proton pump inhibitor (PPI). NEXIUM delayed-release capsules and NEXIUM for delayed-release oral suspension are indicated for the: • Short-term treatment in the healing of erosive esophagitis (EE) in adults and pediatric patients 12 years to 17 years of age. ( 1.1 ) • Maintenance of healing of EE in adults. ( 1.2 ) • Short-term treatment of heartburn and other symptoms associated GERD in adults and pediatric patients 12 years to 17 years of age. ( 1.3 ) • Risk reduction of nonsteroidal anti-inflammatory drugs (NSAID)-associated gastric ulcer in adults at risk for developing gastric ulcers due to age (60 years and older) and/or documented history of gastric ulcers. ( 1.4 ) • Helicobacter pylori eradication in adult patients to reduce the risk of duodenal ulcer recurrence in combination with amoxicillin and clarithromycin. ( 1.5 ) • Long-term treatment of pathological hypersecretory conditions, including Zollinger-Ellison syndrome in adults. ( 1.6 ) NEXIUM for delayed-release oral suspension is indicated for the: • Short-term treatment in the healing of EE in pediatric patients 1 year to 11 years of age and of EE due to acid-mediated GERD in pediatric patients 1 month to less than 1 year of age. ( 1.1 ) • Short-term treatment of heartburn and other symptoms associated with GERD in pediatric patients 1 year to 11 years of age. ( 1.3 ) 1.1 Healing of Erosive Esophagitis (EE) Adults NEXIUM delayed-release capsules and NEXIUM for delayed-release oral suspension are indicated for the short-term treatment (4 to 8 weeks) in the healing and symptomatic resolution of diagnostically confirmed EE in adults. For those patients who have not healed after 4 to 8 weeks of treatment, an additional 4- to 8- week course of NEXIUM may be considered. Pediatric Patients 12 Years...

Mechanism: Esomeprazole belongs to a class of antisecretory compounds, the substituted benzimidazoles, that suppress gastric acid secretion by specific inhibition of the H+/K+ ATPase enzyme system at the secretory surface of the gastric parietal cell. Esomeprazole is protonated and converted in the acidic compartment of the parietal cell forming the active inhibitor, the achiral sulphenamide. Because this enzyme system is regarded as the acid (proton) pump within the gastric mucosa, esomeprazole has been characterized as a gastric acid-pump inhibitor, in that it blocks the final step of acid production....

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

4 products under this application
  • NEXIUM · ESOMEPRAZOLE MAGNESIUM EQ 2.5MG BASE/PACKET · FOR SUSPENSION, DELAYED RELEASE, ORAL · Prescription · TE AB
  • NEXIUM · ESOMEPRAZOLE MAGNESIUM EQ 20MG BASE/PACKET · FOR SUSPENSION, DELAYED RELEASE, ORAL · Prescription · TE AB
  • NEXIUM · ESOMEPRAZOLE MAGNESIUM EQ 5MG BASE/PACKET · FOR SUSPENSION, DELAYED RELEASE, ORAL · Prescription · TE AB
  • NEXIUM · ESOMEPRAZOLE MAGNESIUM EQ 40MG BASE/PACKET · FOR SUSPENSION, DELAYED RELEASE, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Esomeprazole" as an intervention, any sponsor and status, largest first.

All 522 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • chronic kidney disease33,708
  • acute kidney injury17,592
  • renal failure14,997
  • drug ineffective11,529
  • gastrooesophageal reflux disease11,038
  • drug dose omission10,970
  • nausea10,406
  • end stage renal disease9,816
  • renal injury8,915
  • pain8,591
  • diarrhoea7,953
  • malaise7,946

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20042,032
20052,746
20063,529
20074,467
20085,251
20096,620
20108,243
201113,211
201222,370
20137,117
20147,345
201510,485
201610,084
20178,080
201821,309
201921,821
20207,600
20216,011
20224,385
20233,285
20243,034
20253,532
20262,234

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Nexium (Esomeprazole Magnesium)

2024 spending

$59.7M

Beneficiaries

20,438

97,946 claims

Per beneficiary

$2,922

$8.85 per unit

View as table
YearSpending
2020$106,028,083
2021$94,196,779
2022$84,185,655
2023$74,209,509
2024$59,728,475

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 777 on PubMed

Sponsor: AstraZeneca

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.